Opposite regulation of piRNAs, rRNAs and miRNAs in the blood after subarachnoid hemorrhage

Rafal Morga 1 · Malgorzata Borczyk 2 · Michal Korostynski 2 · Marcin Piechota 2 · Dzesika Hoinkis 3 · Slawomir Golda 2 · Tomasz Dziedzic 4 · Agnieszka Slowik 4 · Marek Moskala 1 · Joanna Pera 4

Abstract

Multiple classes of small RNAs (sRNAs) are expressed in the blood and are involved in the regulation of pivotal cellular processes. We aimed to elucidate the expression patterns and functional roles of sRNAs in the systemic response to intracranial aneurysm (IA) rupture. We used next-generation sequencing to analyze the expression of sRNAs in patients in the acute phase of IA rupture (first 72 h), in the chronic phase (3–15 months), and controls. The patterns of alterations in sRNA expression were analyzed in the context of clinically relevant information regarding the biological consequences of IA rupture. We identified 542 differentially expressed sRNAs (108 piRNAs, 99 rRNAs, 90 miRNAs, 43 scRNAs, 36 tRNAs, and 32 snoRNAs) among the studied groups with notable differences in upregulated and downregulated sRNAs between the groups and sRNA categories. piRNAs and rRNAs showed a substantial decrease in RNA abundance that was sustained after IA rupture, whereas miRNAs were largely upregulated. Downregulated sRNA genes included piR-31080, piR-57947, 5S rRNA, LSU-rRNA, and SSU-rRNA s. Remarkable enrichment in the representation of transcription factor binding sites was revealed in genomic locations of the regulated sRNA. We found strong overrepresentation of glucocorticoid receptor, retinoid x receptor alpha, and estrogen receptor alpha binding sites at the locations of downregulated piRNAs, tRNAs, and rRNAs. This report, although preliminary and largely proof-of-concept, is the first to describe alterations in sRNAs abundance levels in response to IA rupture in humans. The obtained results indicate novel mechanisms that may constitute another level of control of the inflammatory response.

Key messages

- A total of 542 sRNAs were differentially expressed after aneurysmal SAH comparing with controls
- piRNAs and rRNAs were upregulated and miRNAs were downregulated after IA rupture
- The regulated sRNA showed an enrichment in the representation of some transcription factor binding sites
- piRNAs, tRNAs, and rRNAs showed an overrepresentation for GR, RXRA, and ERALPHA binding sites

Keywords Subarachnoid hemorrhage · Intracranial aneurysm · Small noncoding RNAs · Peripheral blood · RNA sequencing

Introduction

Intracranial aneurysm (IA) rupture results in many systemic effects and strongly influences immune system function. The molecular mechanisms driving the effects of subarachnoid hemorrhage (SAH) remain to be elucidated to improve the management of patients with ruptured IAs. One of the elements of the systemic effects of IA rupture is changes in the transcriptome of peripheral blood cells. To date, protein-coding mRNAs are the RNA class to have been investigated first and most intensively using microarrays initially and then next-generation sequencing techniques [1–4]. However, there is an increasing body of evidence indicating that noncoding
RNAs (ncRNAs) play a crucial role in many pathological conditions. According to their length, ncRNAs are divided into two large categories: long (>200 bp) and small (<200 bp) ncRNAs. Small ncRNAs (sncRNAs) are a highly heterogenic group comprising microRNAs (miRNAs), piwi-interacting RNAs (piRNAs), short interfering RNAs (siRNAs), small nucleolar RNAs (snORs), small nuclear RNAs (snRNAs), promoter-associated small RNAs (PASRs), transfer RNAs (tRNAs), and ribosomal RNAs (rRNAs). In general, these RNAs are regulatory molecules influencing gene transcription, translation, genome integrity preservation, and epigenetic regulation [5–8].

In our previous studies, we focused on the effects exerted by IA rupture on the expression of miRNAs and miRNAs in peripheral blood cells [4, 9]. In this preliminary study, we investigated changes in the expression of small ncRNAs other than miRNAs in peripheral blood cells using deep transcriptome sequencing in a single cohort of patients. To assess time-related changes, patients in the acute (days) and chronic (months) phases of aSAH were included in the study.

Materials and methods

Patients

The studied cohort was described elsewhere [4]. Briefly, patients with aneurysmal SAH were prospectively recruited from consecutive patients of the Departments of Neurology or Neurosurgery and Neurotraumatology, University Hospital, Krakow. Two independent patient groups were analyzed: acute (within the first 72 h after IA rupture) and chronic (within 3–15 months after SAH). Control subjects (C) were recruited from patients in the Department of Neurology who suffered from headaches. Demographic and risk factor data were collected using a dedicated questionnaire.

All subjects were Caucasian. Written informed consent was obtained from all participants (or guardians of participants) before inclusion in the study. The local ethics committee approved the study.

Blood collection and RNA extraction

Venous whole blood was collected before neurosurgical interventions in PAXgene Blood RNA Tubes (PreAnalytiX, GmbH, Switzerland), mixed, and kept at room temperature for at least 2 h. The tubes were subsequently frozen and stored at −70 °C until further processing. Total RNA was purified from blood samples using the PAXgene Blood RNA Kit (PreAnalytiX) according to the manufacturer’s protocol and was treated with DNase. RNA concentrations were measured using a NanoDrop ND-1000 Spectrophotometer (NanoDrop Technologies, Montchanin, DE), and RNA quality was determined by ChiP-based capillary electrophoresis utilizing the Agilent RNA 6000 Nano Kit and an Agilent Bioanalyzer 2100 (Agilent, Palo Alto, CA) according to the manufacturer’s protocols.

Small RNA sequencing

sRNA library preparation and sequencing were performed with Illumina sequencing technology. The sRNA library was generated with the TruSeq Small RNA Library Kit. Briefly, 3′ and 5′ adapters were ligated into 1 μg of total RNA with T4 RNA ligase. Then, reverse transcription was performed with the Illumina sRNA RT-Primer, and cDNA was amplified by PCR (11 cycles) using the Illumina small RNA primer set. The amplified total cDNA library was purified and size selected (insert size 22–30 bp) in 6% Novex TBE gel. The transcriptome libraries were sequenced on a HiSeq2500™ (Illumina) with the following parameters: SE50 (single end) and 10 M clean reads, which yielded a minimum of 500 Mb of raw data per sample (SE50, 10 M, 500 Mb). The sRNA-seq data were submitted to the NCBI Sequence Read Archive (SRA): SRP150595. The detailed analysis of the regulated miRNA has been published elsewhere [9]. In this study, we focus on multiple different classes of sRNAs that are differentially expressed in the blood in response to IA rupture. We reanalyzed profiles of miRNA regulation to compare and contrast with the other classes.

sRNA data analysis

The sequence read quality was evaluated using the FastQC (0.11.5) quality filter module. The raw reads were mapped to the reference human genome hg38 using BWA (version 0.7.17). The expression levels were quantified using IntersectBed (v2.28.0) and GTF with data from the DASHR database of human small noncoding RNAs in human tissues and cell types (v2.0). sRNA transcripts with counts per million (CPM) values above 2 in at least 10 samples were considered detectable and were used for further analysis.

Identification of differentially expressed sRNA

All statistical analyses were performed using R software v3.4.3. A normalization step was performed because the total number of reads from different experiments was not the same, and variations in the number of reads of individual sRNA may be attributable to sequencing depth. The total clone count was the sum of frequencies of all the residual unique sequences after filtering. Differential expression was analyzed with the quasi-likelihood F-test from the edgeR package (v.3.6.8). The false discovery rate (FDR) was estimated using the Benjamini-Hochberg method. Sequences with FDR < 0.1 were considered to be differentially expressed. Statistical
power of the analysis was estimated with two methods: (1) according to Hart et al. [10] with depth = 676, cv = 0.47 and was 33.6% for 1.2 fold-change (FC), 85% for 1.5 FC, 97.2% for 1.7 FC, and 99.86% for 2 FC; (2) by shuffling sRNA counts, simulating a given FC in a subset of the dataset and detecting the number of changed sequences that passed the 0.1 FDR. Here, 99.4% of sequences were detected at simulated 1.2 FC in 10% of dataset. Sequences with fold-change > 1.2 compared with controls (C) were considered regulated in particular conditions. After the fold-change filter was applied, 516 sequences remained.

Conservation analysis

For conservation analysis, phastCons scores for multiple alignments of 99 vertebrate genomes (list: http://hgdownload.cse.ucsc.edu/goldenpath/hg38/phastCons100way/) to the human genome were averaged across each sRNA sequence (noncovered bases were given a score of 0). Conservation scores have values between 0 and 1 (1: means that all bases are conserved in all 100 genomes).

Overrepresentation of ChIP-seq-defined DNA features

To investigate the biological mechanisms involved in the control of sRNA expression after IA rupture, we searched for overrepresented transcription factor binding sites on genomic regions of the regulated transcripts. We employed available ChIP-seq data (Consortium, 2012) using the online resource seqinspector (seqinspector.cremag.org). The batch coordinate conversion (liftOver) was used to convert genome coordinates between hg38 and hg19 assemblies (516 regulated sRNAs were converted to 508). The set of genomic coordinates from sRNA-seq was used as an input. The background reference set was defined as 455 randomly selected, nonregulated sRNAs with mean expression levels in the blood similar to those of the regulated sRNAs. The difference between the query and reference datasets was calculated by t test with the use of Bonferroni correction. Where applied, the difference between class composition was analyzed using the χ2 test.

Results

Alterations in sRNA abundance levels in response to IA rupture

The study comprised 19 patients in the acute phase of IA rupture (RAA), 20 patients in the chronic phase of SAH (RAC), and 20 control subjects (C) (Table 1). The clinical characteristics of the patients are published elsewhere [4].

We used NGS to comprehensively examine the expression levels of sRNAs derived from the peripheral blood. Normalized miRNA abundance levels (CPM) were measured for the small transcripts annotated in the GRCm38.p13 genome release. A total of 1766 genes were detected at the threshold of CPM > 2 in at least 10 samples. To annotate the genome-mapped sRNA reads, we referred to the UCSC Genome Browser and Ensembl database. For differential expression detection, results were considered significant if their FDR was < 0.01. Comparing RAA, RAC, and controls, we found 542 differentially expressed sRNAs that included 516 sRNAs with an abundance change of more than 1.2-fold compared with the control. This list of 516 genes was used for further analysis.

The first goal of the analysis was to investigate classwise sRNA expression profiles of both the acute and chronic phases after IA rupture, as well as effects that were sustained between both timepoints. To identify sRNAs that were specifically regulated at each analyzed timepoint, sRNAs were considered regulated if they met the fold-change > 1.2 condition in one or both comparisons (Supplementary Table S1). We identified 105 sRNAs that were regulated in the acute phase and 77 sRNAs that were regulated in the chronic phase in comparison with controls. A total of 286 sRNAs were differentially expressed in both experimental groups compared with the control, suggesting that most of the investigated sRNAs underwent prolonged changes in their abundance in blood after IA rupture (Fig. 1).

To further elucidate sRNA regulation by IA rupture, we investigated the direction of change of sRNA expression in the acute and remote SAH period. Among the sRNAs regulated in the acute phase or in both, most (60 downregulated vs. 45 upregulated and 210 downregulated vs. 76 upregulated, respectively) were downregulated, whereas in the chronic phase-regulated transcripts, most (42 upregulated vs. 35 downregulated) were upregulated. Eighty-one transcripts showed a mixed pattern of expression, where 41 were downregulated in the acute phase and upregulated in the chronic phase, while 7 were upregulated in the acute phase and downregulated in the chronic phase (Fig. 1, Supplementary Table S1).

Analysis of class composition of the regulated sRNAs

We next examined the number of regulated sRNAs of each RNA type. To investigate the specificity of the regulation patterns described, we compared the abundance of each sRNA class with a group of randomly selected, nonregulated sRNAs that included a similar number of sequences as the largest regulated group (n = 233, Fig. 2, Supplementary Table S2).

In general, the class composition of nonregulated sRNAs was clearly distinct from that of downregulated and upregulated sRNAs. Overall, miRNAs, rRNAs, piRNAs, and scRNAs were the most abundant classes, but their numbers
differed between experimental groups. In the case of miRNAs, the number of transcripts was highest within the nonregulated group \((n = 37\) vs. \(n = 3–18\) in other groups). Among the regulated transcripts, sRNAs downregulated in both SAH phases showed a radically different class composition compared with all the other groups, with rRNA and piRNA sequences being overrepresented (rRNA \(n = 75\) vs. \(n = 0–23\) in other groups, piRNA \(n = 68\) vs. \(n = 0–31\) in other

|                          | RAA \((n = 19)\) | RAC \((n = 20)\) | C \((n = 20)\) |
|--------------------------|-----------------|-----------------|-------------|
| Age, years (median, IQR) | 54 (48–62)      | 50 (41–56)      | 55 (50–60) |
| Female, %                | 73.7            | 90.0            | 55.0*       |
| Hypertension, %          | 57.9            | 55.0            | 50.0        |
| Smoking, %               | 31.6            | 40.0            | 30.0        |
| Excessive drinking, %    | 0               | 5.0             | 10.0        |
| Diabetes mellitus, %     | 5.3             | 5.0             | 10.0        |
| Hyperlipidemia, %        | 5.3             | 0               | 15.0        |
| Admission Hunt-Hess score (median, IQR) | 2 (1–3) | 2 (1–3) | 2 (1–3) |
| Aneurysms location       |                 |                 |             |
| Anterior circulation, \(n\) | 17             | 16              |             |
| Posterior circulation, \(n\) | 2              | 4               |             |

RAA, acute phase of intracranial aneurysm (IA) rupture; RAC, chronic phase of IA rupture; C, control subjects; IQR, interquartile range; GCS, Glasgow Coma Scale

*\(p < 0.05\) RAC vs. C

Fig. 1 Timepoint dependence and direction of sRNA expression changes after IA rupture. The diagram in the middle represents the number of small RNAs that were significantly differentially expressed in the tested conditions. A total of 105 sRNAs were differentially expressed only in the blood from RAA patients (acute phase, days; blue shape), 77 sRNAs were differentially expressed only in the blood from RAC patients (chronic phase, months; pink shape), and 286 sRNAs were changed at both timepoints. Bar graphs adjacent to each part of the Venn diagram indicate the direction of sRNA transcript-level changes (blue, percentage of downregulated transcripts; red, percentage of upregulated transcripts; green, percentage of transcripts with a mixed expression profile). Small graphs to the right of each bar illustrate patterns of alterations in expression.
groups). In summary, the class composition analysis showed a specific pattern of sRNA expression regulation, particularly among the downregulated transcripts.

Analysis of sequence conservation of the identified sRNAs

Next, we analyzed how conserved the sequences of the regulated sRNAs are between the human genome and 99 other vertebrate genomes. To this end, we used available phastCons scores [11]. First, we investigated whether sRNA classes are differentially conserved among one another and between nonregulated and regulated sRNAs. This analysis was performed by comparing the 516 regulated sRNAs with a list of 457 nonregulated sRNAs (Supplementary Fig. S1). This analysis revealed that conservation among sRNA sequences is largely class-specific, with tRF3, tRF5, and scRNAs being the least conserved and tRNAs, piRNAs, and mir-5p having the highest numbers of conserved sequences. Out of the highly conserved classes, the piRNAs were over-represented in the downregulated sRNAs in both the acute and chronic groups.

Binding patterns of regulatory factors to genomic positions of regulated sRNAs

We searched for overrepresented transcription factor binding sites in genomic regions encoding the regulated sRNAs. In general, sRNA sequences exhibit strong ChIP-seq signals from multiple transcriptional factors, possibly due to the high transcriptional activity of these loci.

We compared the lists of upregulated and downregulated sRNAs in either acute, chronic, or both phases, with a list of nonregulated sRNAs serving as a reference. The regions expressing sRNAs downregulated in peripheral blood cells of patients after IA rupture (both acute and remote period) exhibit a significant overrepresentation of ChIP-seq signals for a set of transcription factors (TFs) (Supplementary Table S3). Among these TFs, overrepresentation was detected in more than one experiment for three factors (Fig. 3a): glucocorticoid receptor (GR), retinoid x receptor alpha (RXRA), and estrogen receptor alpha (ERALPHA). No overrepresentation of TF binding sites was detected for any other group of regulated sRNA sequences.

A histogram of GR ChIP-seq average coverage is shown in Fig. 3b. The peak signal is concentrated near the start of the
Fig. 3  Overrepresentation of transcription factor (TF) binding sites in sRNAs downregulated after IA rupture with glucocorticoid receptor (GR) as an example. a Overrepresentation of TF binding sites was detected only in the sRNAs that showed downregulation in both phases. Nonregulated sRNAs were used as references. b Histogram of averaged ChIP-seq signal of downregulated sRNA sequences for GR (blue line). Upregulated sRNA sequences (red line), nonregulated sRNA sequences (green line, reference), and a genome background (gray line) are shown for comparison. c GR ChIP-seq signal for LSU-rRNA_Hsa-L12 genome location is shown as an example. The GR binding peak corresponds well with the rRNA sequence. d Class composition (in percentage) of downregulated sRNA sequences with detected representation of GR binding sites (uppermost panel, n = 61). This composition was compared with the class composition of downregulated sRNAs without GR binding sites detected (second panel, n = 149). Two bottom panels show the class composition of upregulated and nonregulated sRNAs. Color-coding as in Fig. 2, with the darkest orange added for tRNAs. The classes with > 20% abundance percentage are indicated.

sRNA sequence. An example ChIP-seq signal of an sRNA (large ribosomal subunit rRNA) with the highest GR signal is shown in Fig. 3c.

Classwise analysis indicated that the tRNA (particularly loci with tRNA-His-GTG-1) is the sRNA subtype with enriched representation of GR-binding in its vicinity (comparison of class composition of sRNAs downregulated in both phases that have vs. those that do not have GR ChIP-seq signal coverage, chi-square 59.77, p value < 0.00001). Many rRNAs (5S, SSU, and LSU) and piRNAs (including piR-44984, piR-36233, piR-31080, piR-48966, piR-48966, piR-57947, and piR-36329) also showed GR binding-site overrepresentation (Fig. 3d). A similar pattern was observed for the other TFs (Supplementary Fig. S2).

Discussion
To the best of our knowledge, this report is the first to describe the effects of IA rupture on sRNA expression in peripheral blood cells. Transcriptome analysis revealed that alterations in the expression levels of sRNAs were present both in the acute and remote periods after SAH. Although the direction of observed changes was generally preserved, for a small subset of
sRNAs, the directionality differed between phases. Since our knowledge on the functionality of particular RNA molecules is notably scarce, interpreting the obtained results remains difficult. Notably, the downregulated transcripts were predominantly rRNAs and piRNAs.

At the cellular level, stress leads to alteration of cell metabolism and reorganization of nuclear architecture, reflecting the simultaneous inhibition and activation of specific nuclear pathways. Since ribosome biosynthesis is a highly energy-consuming process, one strategy to preserve energy homeostasis is the attenuation of ribosomal biogenesis and rRNA synthesis. This can be achieved by downregulating rDNA transcription, pre-rRNA processing, and epigenetic regulation by adjusting the number of active genes. The size of the nucleolus, which plays a crucial role in ribosome biogenesis, is positively correlated with the rRNA synthesis rate, which depends on cell growth and metabolism [12–14]. Thus, we can assume that the observed downregulation of rRNA is a response of peripheral blood cells to stress caused by IA rupture. This finding corresponds with lymphopenia present in SAH patients. Although we observed a simultaneous increase in monocyte count, considering the absolute numbers of cell classes, it seems that the drop in lymphocyte count is more prominent. Moreover, we have previously reported in the acute phase of SAH a downregulation of HEATR1 (HEAT repeat-containing protein 1) mRNA. HEATR1 protein is involved in the regulation of ribosomal biogenesis, and its downregulation causes cell cycle arrest [4].

Another type of downregulated sRNA is piRNAs. These RNAs are predominantly recognized as molecules responsible for the regulation of the activity of transposons, which constitute approximately 45% of the human genome. Since transposons can mobilize in the genome and cause genomic instability, piRNAs are recognized as molecules crucial for genome stability and the prevention of mutagenesis. Moreover, piRNAs are involved in epigenetic control via DNA methylation and histone modification [6, 15]. This control was demonstrated not only in germline cells but also in somatic and cancer cells [16, 17]. The significance of the observed alterations in piRNA expression and their pathophysiological role after SAH remains to be elucidated. Transposons are implicated in the immune response in multiple sclerosis and other autoimmune conditions [18]. Rajan et al. showed altered piRNA expression in the heart during hypertrophy induction in a rat model. These researchers also found differences in the abundance levels of circulating piRNA in the serum of patients with myocardial infarction, suggesting the importance of piRNA-mediated mechanisms in various pathophysiological conditions affecting the cardiovascular system [19]. Dysregulation of piRNA expression has been shown in many different human malignancies [20]. Additionally, in a rat cerebral ischemia model, alterations in piRNA expression were demonstrated in the ischemic cortex [21].

Another interesting observation is differences in conservation scores among different classes of regulated sRNAs, particularly the low conservation score of tRFs compared with the high conservation score of tRNAs. tRNAs together with rRNAs are housekeeping RNAs. These RNAs are responsible for the supplying amino acids to ribosomes and other biochemical pathways and regulating cell apoptosis by cytochrome binding, and they are highly conserved in evolution [22]. Interestingly, the largest tRNA gene cluster is located in the major histocompatibility complex (MHC) region, which is crucial in adaptive and innate immunity [23]. tRFs are derivatives of tRNAs and are known to accumulate in response to cellular stress. tRFs play an important regulatory role in gene expression (at the level of transcription and translation), apoptosis, and cell survival. There is a growing body of evidence indicating that tRF generation is not a random process, and their function may vary between cell types [24–26]. For instance, in monocytes, tRF-5030c via PIWI protein interaction was shown to cause histone H3K9 methylation [27]. Veneziano et al. found significant dysregulation of tRF expression in human chronic lymphocytic leukemia, suggesting that this class of molecule could at least serve as a disease biomarker [28]. Thus, one can speculate that alterations in tRF expression are specific for the systemic response to SAH.

Analysis of TFBSs among regulated sRNAs revealed significant overrepresentation of ChIP-seq signals for a range of transcription factors. The top 3 overrepresented TFBSs, namely, GR, ERALPHA, and RXRA, belong to the superfamily of nuclear receptors, and they are all overrepresented among downregulated sRNA classes.

GR is expressed in nearly all vertebrate cells. GR is involved in the regulation of thousands of genes and participates in different aspects of development, metabolism, stress response, and other processes. GR can interact with DNA directly or via proteins. Additionally, there are many coregulators of these interactions, and most GR target genes are cell type-specific. As a result, the final response to GR stimulation is context-specific and distinct from the cell type [29]. Glucocorticoids (GCs) are endogenous agonists of GR. GCs are known to exert potent regulatory effects on the immune system and inflammatory response. GCs are negative regulators of thymopoiesis, possess lympholytic properties, affect T cell activation and polarization (promoting Th2 and Treg), and influence monocyte function [30, 31]. Increases in circulating GC levels caused by the activation of the hypothalamic-pituitary-adrenal axis (HPAA) were shown in cerebral injuries. A dysregulation of HPAA in SAH patients with an abnormal diurnal cortisol profile was reported [32, 33]. In an ischemic stroke model, Courties et al. demonstrated that activation of HPAA with high systemic levels of GCs affected lymphopoiesis by inducing GR-dependent apoptosis in thymic T cells and in B-cell progenitors [34]. Similar effects of traumatic brain injury on T cells were reported [35].
results suggest that GR may also play a regulatory role by interacting with some sRNAs.

Additionally, the retinoid X receptor (RXR) plays a role in the regulation of the immune system. The RXR agonists decrease apoptosis of T cells and promote Th2 polarization, whereas disruption of the RXRA gene in mice resulted in attenuation of T-cell proliferation and promotion of their apoptosis [36]. In addition, disruption of RXR function in macrophages impaired phagocytosis, and RXR activation increased the expression of TGFβ1 [37]. In rodent models of SAH and brain ischemia, activation of RXR played a protective role in damping neuroinflammation [38–40]. In human carotid atherosclerotic plaques, decreased expression of RXR in macrophages and smooth muscle cells was associated with the severity of atherosclerosis [41].

It is widely recognized that estrogen receptors (ERs), including ERALPHA, have prominent effects on immune function in both innate and adaptive immune responses. ERALPHA is expressed in a variety of immune cells and plays an important role in the modulation of cytokine production, cytokine receptor expression, and the activation of effector cells. In general, the stimulation of ERALPHA exerts anti-inflammatory effects. The significance of ERALPHA-mediated signaling in autoimmune disorders is well recognized [42]. Estrogens are known to play a neuroprotective role in stroke, primarily attenuating the inflammatory response [43–45]. The current results indicate that the immunity-related function of ERALPHA can be mediated by interactions with sRNAs.

Our study has a number of limitations. One limitation is the limited sample size. However, the numbers of patients investigated here (n = 59) and in other studies focused on miRNAs are largely comparable, with other studies including from 24 up to 183 participants [46–49]. Furthermore, presented results have not been validated in an independent cohort, thus should be considered proof-of-concept. Further studies are needed to evaluate the reproducibility of observed chronic dysregulation of sRNA levels in IA rupture. Next, the interpretation of the obtained results is speculative to a certain extent. The current knowledge about the role played by sRNAs in humans remains highly limited. In addition, transcripts often exist at multiple less-annotated loci and without full functional description of the products. Overrepresentation of TFBSs highly transcribed loci has been previously reported and remains a plausible explanation of the observed phenomenon [50]. Interestingly, a prominent overrepresentation of GR among TFBSs in regulated sRNAs corresponds with our understanding of the role played by GCs in acute stress and immune/inflammatory reactions.

In the light of discussed limitations, presented results should be considered a proof-of-concept study. Our main observations are the differences in sRNA expression between the experimental and control groups and the result that the down-regulation of many sRNA transcripts persists in the chronic phase after IA rupture. These should further be validated in a separate, preferably larger, cohort of patients. If the results are further validated, there is a translational clinical potential in the presented observations. Namely, levels of sequences of various sRNA classes (such as rRNA, tRNA, miRNA) could serve as potential IA biomarkers; however, further studies are needed. The interpretation of the observed differences may change when better genome annotations and functional descriptions of the small RNAs are available.

In conclusion, the results of this study provide novel insights into sRNA regulation in relation to the systemic inflammatory response after IA rupture. Specifically, we found that SAH is associated with the downregulation of sRNAs that are involved in the regulation of transcription and translation processes. These alterations in the expression levels of some sRNA classes are probably dependent on the activity of the nuclear receptors GR, ERALPHA, and RXRA.

Availability of data and material The RNA-seq data were submitted to the NCBI Sequence Read Archive (SRA): SRP150595. Other datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability Not applicable

Authors’ contributions RM, MK, and JP contributed to the study design and acquisition of the data. RM, MB, MK, MP, DH, SG, TD, and JP contributed to the data analysis and manuscript preparation. All authors contributed to the data interpretation and approved the final version of the manuscript.

Funding information This work was supported the National Science Centre under Grant No. 2014/13/B/NZ4/00148 (JP).

Compliance with ethical standards

Conflict of interest The authors declare that they have no competing interests.

Ethics approval The study was approved by the Bioethics Committee of the Jagiellonian University.

Consent to participate Written informed consent was obtained from all participants (or guardians of participants) before inclusion in the study.

Consent for publication All authors gave their consent for publication.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Baumann A, Devaux Y, Audibert G, Zhang L, Bracard S, Colnat-Coubois S, Klein O, Zannad F, Charpentier C, Longrois D, Mertes PM (2013) Gene expression profile of blood cells for the prediction of delayed cerebral ischemia after intracranial aneurysm rupture: a pilot study in humans. Cerebrovasc Dis 36:236–242

2. Pera J, Korostynski M, Golda S, Piechota M, Dzbej K, Krzyszewski T, Dziedzic T, Moskala M, Przewlocki R, Szczdulik A et al (2013) Gene expression profiling of blood in ruptured intracranial aneurysms: in search of biomarkers. J Cereb Blood Flow Metab 33:1025–1031

3. Sabatino G, Rigante L, Minella D, Novelli G, Delta Pena GM, Esposito G, Albanese A, Maira G, Marchese E (2013) Transcriptional profile characterization for the identification of peripheral blood biomarkers in patients with cerebral aneurysms. J Biol Regul Homeost Agents 27:729–738

4. Korostynski M, Piechota M, Morga R, Hoinkis D, Golda S, Zygmunt M, Dziedzic T, Moskala M, Slowik A, Pera J (2019) Systemic response to rupture of intracranial aneurysms involves expression of specific gene isoforms. Transl Med 17:141

5. Kaur H, Sarmah D, Saraf J, Vats K, Kalia K, Borah A, Yavgal DR, Dave KR, Ghosh Z, Bhattacharyya P (2018) Noncoding RNAs in ischemic stroke: time to translate. Ann N Y Acad Sci 1421:19–36

6. Taft RJ, Pang KC, Mercer TR, Dinger M, Mattick JS (2010) Non-coding RNAs: regulators of disease. J Pathol 220:126–139

7. Yin KJ, Hamblin M, Chen YE (2014) Non-coding RNAs in cerebral endothelial pathophysiology: emerging roles in stroke. Neurochem Int 77:9–16

8. Chen J, Yue Y (2016) Emerging roles of non-coding RNAs in epigenetic regulation. Sci China Life Sci 59:227–235

9. Korostynski M, Morga R, Piechota M, Hoinkis D, Golda S, Dziedzic T, Slowik A, Moskala M, Pera J (2020) Inflammatory responses induced by the rupture of intracranial aneurysms are modulated by miRNAs. Mol Neurobiol 57:988–996

10. Hart SN, Therneau TM, Zhang Y, Poland GA, Kocher JP (2013) Calculating sample size estimates for RNA sequencing data. J Comput Biol 20:970–978

11. Siepel A, Bejerano G, Pedersen JS, Hinrichs AS, Hou M, Rosenbloom K, Clawson H, Spith J, Hillier LW, Richards S et al (2005) Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res 15:1034–1050

12. Boulon S, Westman BJ, Hutten S, Boisvert FM, Lamond AI (2010) The nucleolus under stress. Mol Cell 40:216–227

13. Tiku V, Antebi A (2018) Nucleolar function in lifespan regulation. Trends Cell Biol 28:662–672

14. Corell CC, Bartek J, Dunr M (2019) The nucleolus: a multiphasic condensate balancing ribosome synthesis and translational capacity in health, aging and ribosomopathies. Cells 8:3869

15. Guo M, Wu Y (2013) Fighting an old war with a new weapon—silencing transposons by Piwi-interacting RNA. IUBMB Life 65:739–747

16. Lee EJ, Banerjee S, Zhou H, Jammalamadaka A, Arcila M, Manjunath BS, Kosik KS (2011) Identification of piRNAs in the central nervous system. RNA 17:1090–1099

17. Ross RJ, Weiner MM, Lin H (2014) PIWI proteins and PIWI-interacting RNAs in the soma. Nature 505:353–359

18. Saleh A, Macia A, Muotri AR (2019) Transposable elements, inflammation, and neurological disease. Front Neurol 10:894

19. Rajan KS, Velmurugan G, Gopal P, Ramprashat T, Babu DD, Krishika S, Jenifer YC, Freddy A, William GJN, Kalpana K et al (2016) Abundant and altered expression of Piwi-interacting RNAs during cardiac hypertrophy. Heart Lung Circ 25:1013–1020

20. Liu Y, Dou M, Song X, Dong Y, Liu S, Liu H, Tao J, Li W, Yin X, Xu W (2019) The emerging role of the piRNA/piwi complex in cancer. Mol Cancer 18:123

21. Dhapar A, Nakka VP, Vemuganti R (2011) Altered expression of PIWI RNA in the rat brain after transient focal ischemia. Stroke 42:1105–1109

22. Pang Y, Mao C, Liu S (2018) Encoding activities of non-coding RNAs. Theranostics 8:2496–2507

23. Dhabhi JM (2015) 5′tRNA halves: the next generation of immune signaling molecules. Front Immunol 6:74

24. Shen Y, Yu X, Zhu L, Li T, Yan Z, Guo J (2018) Transfer RNA-derived fragments and tRNA halves: biogenesis, biological functions and their roles in diseases. J Mol Med 96:1167–1176

25. Światowt W, Jagodziński PP (2018) Molecules derived from tRNA and snoRNA: entering the degradome pool. Biomed Pharmacother 108:36–42

26. Taxis TM, Kehrl ME Jr, D’Orey-Branco R, Casas E (2018) Association of transfer RNA fragments in white blood cells with antibody response to bovine leukemia virus in holstein cattle. Front Genet 9:236

27. Zhang X, He X, Liu C, Liu J, Hu Q, Pan T, Duan X, Liu B, Zhang Y, Chen J et al (2016) IL-4 inhibits the biogenesis of an epigenetically suppressive PIWI-interacting RNA to upregulate CD1a molecules on monocytes/dendritic cells. J Immunol 196:1591–1603

28. Veneziano D, Tomassello L, Balatti V, Palamarchuk A, Rassenti LZ, Kipps TJ, Pekarsky Y, Croce CM (2019) Dysregulation of different classes of tRNA fragments in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 116:24252–24258

29. Weikum ER, Knuesel MT, Ortlund EA, Yamamoto KR (2017) Glucocorticoid receptor control of transcription: precision and plasticity via allosteroy. Nat Rev Mol Cell Biol 18:159–174

30. Cain DW, Cidlowski JA (2017) Immune regulation by glucocorticoids. Nat Rev Immunol 17:233–247

31. Wang C, Nanni L, Novakov B, Megehlenbrink W, Kuznetsova T, Stunnenberg HG, C反过来, Logie C (2019) Extensive epigenomic integration of the glucocorticoid receptor in primary human monocytes and in vitro derived macrophages. Sci Rep 9:2772

32. Poll EM, Boström A, Bürgel U, Reinges MH, Hans FJ, Gilbach JM, Kreitschmann-Andermahr I (2010) Cortisol dynamics in the acute phase of aneurysmal subarachnoid hemorrhage: associations with disease severity and outcome. J Neurotrauma 27:189–195

33. Zetterling M, Engström BE, Hallberg L, Hillered L, Enblad P, Karlsson T, Rundgren J, Engström E (2011) Cortisol and adrenocorticotropic hormone dynamics in the acute phase of subarachnoid haemorrhage. Br J Neurosurg 25:684–692

34. Courties G, Frodermann V, Honold L, Zheng Y, Herisson F, Schloss MJ, Sun Y, Presseye J, Severe N, Engblom C et al (2019) Glucocorticoids regulate bone marrow B lymphopoiesis after stroke. Circ Res 124:1372–1385

35. Tapp ZM, Godbout JP, Kokiko-Cochran ON (2019) A tilted axis: maladaptive inflammation and HPA axis dysfunction contribute to consequences of TBI. Front Neurol 10:345

36. Stephensen CB, Borowsky AD, Lloyd KC (2007) Disruption of Rxa gene in thymocytes and T lymphocytes modestly alters lymphocyte frequencies, proliferation, survival and T helper type 1/type 2 balance. Immunology 121:484–498

37. Natrajan MS, de la Fuente AG, Linehan E, Nunez V, Johnson KR, Wu T, Fitzgerald DC, Ricote M, Bielekova B et al (2015) Retinoic X receptor activation reverses age-related deficiencies in myelin debris phagocytosis and remyelination. Brain 138:3581–3597

38. Corro M, Endo Y, Ohita K, Sakurada S, Bagetta G, Amano D (2015) Activation of RFX/RPARP underlies neuroprotection by bexarotene in ischemic stroke. Pharmacol Res 102:298–307

39. Loppi S, Kolosowski N, Kärkkäinen O, Korhonen P, Huiskonen M, Grubman A, Dhungana H, Wojciechowski S, Pomeschik Y,
Giordano M et al (2018) HX600, a synthetic agonist for RXR-Nurr1 heterodimer complex, prevents ischemia-induced neuronal damage. Brain Behav Immun 73:670–681
40. Zuo Y, Huang L, Enkhjargal B, Xu W, Umut O, Travis ZD, Zhang G, Tang J, Liu F, Zhang JH (2019) Activation of retinoid X receptor by bexarotene attenuates neuroinflammation via PPARγ/SIRT6/FoxO3a pathway after subarachnoid hemorrhage in rats. J Neuroinflammation 16:47
41. Giaginis C, Klonaris C, Katsargyris A, Kouraklis G, Spiliopoulou C, Theocharis S (2011) Correlation of peroxisome proliferator-activated receptor-gamma (PPAR-gamma) and retinoid X receptor-alpha (RXR-alpha) expression with clinical risk factors in patients with advanced carotid atherosclerosis. Med Sci Monit 17:CR381–CR391
42. Cunningham M, Gilkeson G (2011) Estrogen receptors in immunity and autoimmunity. Clin Rev Allergy Immunol 40:66–73
43. Manwani B, Liu F, Scranton V, Hammond MD, Sansing LH, McCullough LD (2013) Differential effects of aging and sex on stroke induced inflammation across the lifespan. Exp Neurol 249:120–131
44. Roy-O'Reilly M, McCullough LD (2018) Age and sex are critical factors in ischemic stroke pathology. Endocrinology 159:3120–3131
45. Ahnstedt H, McCullough LD (2019) The impact of sex and age on T cell immunity and ischemic stroke outcomes. Cell Immunol 345:103960
46. Jin H, Li C, Ge H, Jiang Y, Li Y (2013) Circulating microRNA: a novel potential biomarker for early diagnosis of intracranial aneurysm rupture a case control study. J Transl Med 11:296
47. Li P, Zhang Q, Wu X, Yang X, Zhang Y, Li Y, Jiang F (2014) Circulating microRNAs serve as novel biological markers for intracranial aneurysms. J Am Heart Assoc 3:e000972
48. Su XW, Chan AH, Lu G, Lin M, Sze J, Zhou JY, Poon WS, Liu Q, Zheng VZ, Wong GK (2015) Circulating microRNA 132-3p and 324-3p profiles in patients after acute aneurysmal subarachnoid hemorrhage. PLoS One 10:e0144724
49. Meeuwsen JAL, van’t Hof FNG, van Rheenen W, Rinkel GJE, Veldink JH, Ruigrok YM (2017) Circulating microRNA profiles in patients with intracranial aneurysms. PLoS One 12:e0176558
50. Teytelman L, Thurtle DM, Rine J, van Oudenaarden A (2013) Highly expressed loci are vulnerable to misleading ChIP localization of multiple unrelated proteins. Proc Natl Acad Sci U S A 110:18602–18607

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.